GILEAD SCIENCES, INC. (GILD)
B
Pipeline Grade
Financial Position (from SEC Filings)
$7,628.0M
Cash & Equivalents
$2,544.0M
Quarterly Burn Rate
$165,985M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE
ATRIPLA |
NDA | Acquired Immunodeficiency Syndrome, Advanced Estrogen Receptor Positive HER2- Breast Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Solid Tumors, Aicardi Goutières Syndrome, AIDS, Arteriosclerosis, Aspergillosis, Aspergillosis, Invasive Pulmonary, B-Cell Malignancies, Breast Cancer, Chronic Hepatitis B, Chronic Hepatitis C, Chronic Hepatitis C Virus, Chronic Lymphocytic Leucemia, Chronic Lymphocytic Leukaemia, Chronic Lymphocytic Leukemia, Chronic Stable Angina, Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumor, Compliance, Medication, Coronary Artery Disease, COVID-19, Covid19, Cystic Fibrosis, Cytomegalovirus Retinitis, Diabetic Glomerulosclerosis, Diabetic Nephropathies, Diffuse Large B-Cell Lymphoma, Diffuse Scleroderma, Drug, Drug Use, Follicular Lymphoma, Fungus Diseases, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gout, HBV, HCV, HCV Infection, Healthy, Healthy Volunteers, Hepatitis B, Hepatitis C, Hepatitis C Infection With HIV |
Upcoming Catalysts
No upcoming catalysts detected for this company.